Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Motley Fool Article ...

<< Previous

Bullboard Posts

Next >>

Comment by Snowballgrowthon Sep 01, 2021 10:07am

127 Views

Post# 33793771

RE:Motley Fool Article ...

MrMugsy wrote: Forget Trillium ... buy these 3 stocks ...

https://www.fool.ca/2021/08/31/forget-trillium-therapeutics-stock-tsxtril-buy-these-pharma-stocks-instead/

--------------------

Knight Therapeutics

Now if you want cheap and strong from your pharma company, look into Knight Therapeutics (TSX:GUD). The company has access to North and Latin American pharmaceutical healthcare products. Yet despite being cheap with a P/E ratio of 11.75, the company has been reporting record revenue again and again.

Most recently, Knight Therapeutics reported a 24% increase in year-over-year revenue, breaking a record in that time. Adjusted EBITDA also increased 23% year over year, but there’s even more growth available to this company.

Part of this growth comes from Health Canada’s approval of its breast cancer therapy. Shares have been growing since the news two months back after falling further and further during the pandemic. Shares are now down 15% in the last year, but up 7% in the last month.

The company remains with a strong balance sheet and a stellar potential upside of 42% as of writing. So this is definitely one Motley Fool investors should consider above Trillium Therapeutics stock.